New therapeutic avenues for Duchenne muscular dystrophy

Lancet Neurol. 2024 Apr;23(4):330-331. doi: 10.1016/S1474-4422(24)00082-6.

Author

Janbernd Kirschner¹

Affiliation

¹ Department of Neuropediatrics and Muscle Disorders, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany. Electronic address: janbernd.kirschner@uniklinik-freiburg.de.

PMID: 38508823
DOI: 10.1016/S1474-4422(24)00082-6

No abstract available

MeSH terms

Humans
Muscular Dystrophy, Duchenne* / therapy